Truth Gate — NailScience (NS-01, 2-Step Nail Restoration Kit)
## ⏳ OPEN — David's verdicts on the 53 claims below are asked on the Launch Center lanenailscience(askns-truth-gate, posted 2026-10-29). Until he answers, every claim is PROVISIONAL: the angle bank cites them as research claims on an open gate, and no new customer-facing line rests on a ⚠ claim as written.
Rule (the house gate): anything in the FALSE list may not appear in brand identity, PDP copy, ads, email or creative briefs — in any paraphrase. TRUE claims are the factual foundation; final wording still passes the compliance officer (CL-00).
Sources: the April copy brief (07, Mode A — David 2026-10-14: no deep-research re-run), the live PDP, the two live prelanders (NS-P2 ranking · NS-P3 Dr. Franks), BRAND.md §1 (formula CLOSED 2026-10-14: what is on the PDP is what is in the pens), §3 (Ladder A), §5 (the proof lines to verify). Raw claims: truth-gate-claims.json.
Order of truth downstream (copy-laws §0): this gate → the live PDP (voice) → the copy brief → the angle bank's evidence → the swipe.
Problems
| id | Claim (⚠ = Claude's check) | Verdict |
|---|---|---|
| p1 | About 1 in 10 adults has toenail fungus (onychomycosis), and the share rises sharply with age — roughly half of people over 70 (the PDP's line). ⚠ Prevalence figures range 2–14% in the general population and 20–50% in the elderly across studies; 'about 1 in 10, far more after 70' is the safe shape. | — |
| p2 | 74% of people with nail fungus report embarrassment; women report severe embarrassment about twice as often as men (44% vs 26%). ⚠ The 74% is Drake et al. 1998 (a 258-patient quality-of-life survey); cite as 'a published patient survey', never as our customers. | — |
| p3 | She hides her feet: no sandals, pools, beaches, pedicures or barefoot moments with a partner; summer is planned around closed-toe shoes (07 §2 'the compulsion to hide'). | — |
| p4 | The 'nothing works' exhaustion: creams, pens, vinegar soaks, tea tree oil, Vicks — a little improvement, then relapse; every new product is another risk of wasted money and hope; trust in the whole aisle is gone (07 §2, the #1 objection in §24). | — |
| p5 | Fear of spread: to the other nails, and to family through shared showers and towels; thick nails catch on socks and press inside shoes (07 §2). | — |
| p6 | Progress is invisible for months, which is why people quit; an early visible milestone (softer, thinner nail; a clear band at the base) is what keeps them on the product (07 §6, §24 objection 3). | — |
| p7 | Oral antifungals (terbinafine / itraconazole) cure 70–90% but need liver-function blood tests and carry taste or smell loss, mood effects and rare liver injury; this market refuses them for what doctors call a cosmetic problem (07 §5). ⚠ Liver injury on terbinafine is rare (~1 in 50,000–120,000 courses) and taste disturbance ~3%: 'rare but documented', never 'liver failure' as the expected outcome. | — |
| p8 | Prescription lacquers (Jublia / Penlac / Kerydin) are FDA-approved but Jublia can cost up to about $1,000 a bottle without insurance, insurers often deny it as cosmetic, and 48-week courses drive dropouts (07 §5). ⚠ List price ≈ $700–$1,000 for 4–8 ml: 'up to about $1,000'. | — |
| p9 | A toenail takes 9–18 months to grow out completely, so a 'clear in 21 days' promise is biologically impossible (07 §5–6, the PDP: 'no brand can cheat biology'). | — |
Rivals (facts only, attributed — CL-13: never a named rival as the target of a headline)
| id | Claim (⚠ = Claude's check) | Verdict |
|---|---|---|
| c1 | Generic OTC antifungal creams (clotrimazole, terbinafine cream) are labeled for athlete's foot on the skin around the nail, not for the nail plate, which they cannot penetrate (07 §5). | — |
| c2 | Antifungal pens carry 25% undecylenic acid — the right active at the top OTC strength — painted onto a thick, unprepared nail; many carry a label disclaimer that the product is not effective on the nail itself (07 §5, the NS-P2 ranking's #3). | — |
| c3 | Crystal Flush's topical active is tolnaftate 1%, which the FDA OTC monograph lists for athlete's foot, jock itch and ringworm — not nails; buyers found the disclaimer after paying $115–140, and Truth-in-Advertising complaints + BBB investigations followed (07 §5). ⚠ Named rival: facts attributed to public records only. | — |
| c4 | Kerassentials' directions require four applications a day, which its video sales letters and landing pages did not disclose; refund disputes and BBB complaints followed (07 §5). ⚠ Named rival: attribute. | — |
| c5 | Kerasal uses the urea softening step but has no antifungal: the nail looks better, then the fungus comes back ('gets you halfway there, then stops' — NS-P2 #2). Kerasal calls itself the #1 dermatologist-recommended nail-renewal brand. ⚠ That '#1' is Kerasal's own survey claim — attribute it to them. | — |
| c6 | Home remedies (Vicks, vinegar, tea tree, Listerine soaks) have active concentrations far too low, demand 30-minute daily soaks, and in the small studies that exist about 20–30% improve over 12+ months (07 §5). | — |
| c7 | The three failure patterns across every rival: promising 21–30 days, skipping the softening step, hiding the 'not for nails' disclaimer (07 §5). | — |
| c8 | A September 2025 FDA warning letter to Jublia's maker for implying a rapid cure in advertising (07 §16). ⚠ UNVERIFIED by Claude — not in copy until the letter is on file. | — |
The noun and the cause
| id | Claim (⚠ = Claude's check) | Verdict |
|---|---|---|
| x1 | THE NOUN — the Keratin Shield: the nail plate is dense, packed keratin built to keep liquids out; a topical antifungal sits on top while the fungus lives in the nail bed underneath. The failure was never the strength of the medicine, it was delivery (07 §6; the PDP: 'like rubbing antibiotics on a cast'; NS-P2: 'your toenail is built like a shield'). | — |
| x2 | Dermatophytes in the nail form biofilms whose matrix makes them many times more resistant to antifungals than free-floating cells, with pumps that expel the drug (07 §6). ⚠ The brief's '2,000×' is a general biofilm figure (studies cite 10–1,000×): 'many times more resistant', no number. | — |
| x3 | The two-step logic — soften and open the nail first, then treat underneath — is the sequence dermatology uses for chemical nail avulsion; this kit brings it home (07 §6, §16). | — |
| x4 | Step 1 (urea + lactic acid + propylene glycol) softens and thins the nail plate, opens micro-channels and carries the active deeper: urea is a clinically validated keratolytic, lactic acid induces a porous microstructure in nail keratin, and propylene glycol raised an antifungal's solubility 12-fold and tissue accumulation 3-fold in a penetration-enhancer screening (07 §6, §8). ⚠ The 12× / 3× figures are one in-vitro screening with ciclopirox: 'in a lab study', never a nail-cure number. | — |
| x5 | Step 2: 25% undecylenic acid, the maximum OTC antifungal concentration (FDA OTC monograph 21 CFR 333), plus tea tree, oregano, manuka and clove oils — broad-spectrum against dermatophytes (07 §6, §8; BRAND §1 formula CLOSED 2026-10-14). | — |
| x6 | The Step 1 trio is the same keratolytic approach as Kerasal's renewal formula; this kit pairs it with a maximum-strength antifungal second step — the only at-home kit that does both (07 §9–10; the PDP: 'the only kit that opens the nail first, then treats underneath'). ⚠ 'Only' rests on the brief's survey of rivals: 'the only kit we know of' unless David wants the flat 'only'. | — |
| x7 | '2-Step Penetration Technology™' is the PDP's name for the system. ⚠ ™ is a use claim, not a registration — the officer's question, not a copy constraint. | — |
Ingredient studies
| id | Claim (⚠ = Claude's check) | Verdict |
|---|---|---|
| i1 | 20% urea + 2% butenafine cream for 16 weeks: 88% cure vs 0% placebo in a 60-patient double-blind trial of great-toenail onychomycosis, no relapses at one year (07 §8). ⚠ Syed et al. 1998 — the antifungal was butenafine, not undecylenic acid: evidence for the softening step, never this kit's cure rate. | — |
| i2 | Texture-analyzer studies on bovine hoof membrane (the accepted in-vitro nail model): the higher the urea concentration, the less force it takes to puncture — nail softening confirmed (07 §8). | — |
| i3 | A multicenter double-blind RCT, 493 patients, 24 weeks, on a urea / lactic acid / propylene glycol solution: 27.2% mycological cure vs 10.4% placebo (p = 0.0012), patient-reported improvement from week 2 (07 §8, §15). ⚠ This is the K101 / Emtrix (Nalox) trial, a different product with the same trio: cite as the trio's evidence, attributed. | — |
| i4 | Faergemann & Swanbeck 1989: 21 of 23 patients improved on a urea / lactic acid / propylene glycol solution applied twice daily for up to six months (2 complete cures, 11 marked improvements) (07 §8). | — |
| i5 | Undecylenic acid: clinical and mycological cure in 53% vs 7% of untreated controls in a 104-patient tinea pedis trial; decades of safety history including WWII military medicine (07 §8, §16). ⚠ 53% is athlete's foot (skin), not nails — never a nail-cure number. | — |
| i6 | A tea tree + oregano + vitamin E nail oil: 78.5% complete cure at 12 months in a 20-patient study (University of Bologna), no side effects (07 §8, §15). ⚠ n = 20, open-label: 'a small clinical study'. | — |
| i7 | Oregano oil lacquer completely inhibited dermatophyte growth in vitro (fungicidal); clove bud oil (eugenol) distorts and shrinks dermatophyte spores in vitro; East Cape manuka oil is up to 33× stronger than tea tree against certain bacteria (07 §8). ⚠ In-vitro and bacterial findings: never a patient-outcome number. | — |
| i8 | A manuka oil spray, 12-week post-marketing study (NL / BE / UK): Onychomycosis Severity Index improved 26.8%, 67% significantly improved, 99% reported no discomfort (07 §8, §15). ⚠ Post-marketing, no placebo arm. | — |
Benefits and timelines (what we promise)
| id | Claim (⚠ = Claude's check) | Verdict |
|---|---|---|
| b1 | Visible change within weeks: softer, thinner, less discolored nail as Step 1 clears damaged nail material — the PDP's 'see the yellow start fading in 2–4 weeks' (07 §6, §9; PDP). | — |
| b2 | A band of clear new nail at the base is the first proof it is working — the PDP's 'new clear growth shows at the base by week 6–8' (07 §6, §23; PDP). | — |
| b3 | Full clearance takes months because the nail has to grow out (9–18 months for a toenail) — and the brand says so; the honest timeline is a trust signal (07 §24 objection 3; PDP 'no brand can cheat biology'). | — |
| b4 | No pills, no blood tests, no liver monitoring, no drug interactions: a topical system, nothing reaches the bloodstream (07 §9, §24 objection 5). | — |
| b5 | Sixty seconds, twice a day (the PDP's routine); dries fast, doesn't stain (a PDP review line). | — |
| b6 | 'Works when creams, polishes and pens failed — because it opens the nail first' (the PDP's lead benefit; 07 §9). | — |
| b7 | Stop worrying about spreading it to other nails, your partner or your family (07 §9). ⚠ A contagion promise: 'treats the nail; the reinfection checklist is yours' is the safe shape. | — |
| b8 | Positioning: cosmetic nail restoration, 'not a cure' (07 header, §14) — while the PDP says 'kills the fungus underneath' and 'the fungal colony'. ⚠ The two conflict: David picks the register (the officer rules on the words). | — |
Proof and persons on the live pages
| id | Claim (⚠ = Claude's check) | Verdict |
|---|---|---|
| s1 | PDP: '★ 4.9 · 200,000+ verified customers'. ⚠ The May copy said '40,000+' (BRAND §5); neither matches the store's order history — David's call. | — |
| s2 | PDP: '658 clinicians recommend NailScience'. ⚠ No source on file. | — |
| s3 | PDP 'As featured in': Bustle, BAZAAR, FLAUNT, marie claire, Mashable, OK! — the prelanders say Forbes, The New York Times, CNN, USA TODAY, healthline, Women's Health. ⚠ Two different lists, no placements on file (the house rule: fictional call-letters, never real mastheads without a placement). | — |
| s4 | NS-P3: 'Excellent · based on 3,214 reviews · Trustpilot'. ⚠ No Trustpilot profile on file (BRAND §5 'verify at the Truth Gate'). | — |
| s5 | The formulator persona differs by page: 'Dr. Miriam Patel, DPM, board-certified podiatrist, 14 years watching patients / 18 years in practice' (PDP) · 'Dr. Jamie Franks, podiatrist, 15 years, New York' (NS-P3) · 'Dr. Diana Hollis, Pharm.D., 14 years' (NS-P2). ⚠ Three fictional doctors across one funnel; the house line on fabricated records is David's — at minimum one persona per funnel. | — |
| s6 | PDP: before/after photos and customer videos — 'real customers, same lighting, same camera, 90 days apart, unedited'. ⚠ Provenance of the April assets is not on file. | — |
| s7 | NS-P2: 'The one that made women cry in the comments'. ⚠ The account's ads carry no public comments (dynamic creative) — no comments on file. | — |
| s8 | Undecylenic acid was used by the U.S. Army in WWII against soldiers' foot infections (NS-P3, 07 §8) — TRUE in the literature (military tinea pedis use). | — |
Offer
| id | Claim (⚠ = Claude's check) | Verdict |
|---|---|---|
| o1 | Ladder A (BRAND §3, locked 2026-10-14): $29.99 a kit · $59.98 for 3 · $89.97 for 5 · monthly $24.99 on 29next. ⚠ The PDP today shows $24.99 / $19.99 / $17.99 per kit ('Save $25 / $90 / $160') — verify which ladder is live before any price goes in copy. | — |
| o2 | 30-Day Money-Back Guarantee, everywhere (the house law, David 2026-10-14) — the brief's 60–90-day suggestion is overruled. | — |
| o3 | Try before you buy: one kit ships for $6.99, $24.99 on day 14, a fresh kit every 30 days, cancel any time with one click (the PDP trial row, 29next campaign 1494). | — |
| o4 | The PDP banner: 'BLACK FRIDAY · DISCOUNT: SECRET50 · ENDS IN <timer>'; NS-P2: 'Try NailScience Today for 50% OFF'. ⚠ A code in copy must be real in Shopify with a real expiry (no fake scarcity). | — |
| o5 | Free US shipping, ships today; 3 pens = one month (BRAND §1). | — |
✅ TRUE — the foundation
_Filled from David's verdicts (ask ns-truth-gate)._
🚫 FALSE — banned in any paraphrase
_Filled from David's verdicts._
💬 FEEDBACK
_David's notes → the fix._